HIF1A and plasma cell myeloma: HK2 has also been found to contribute to an anti-apoptotic effect in myeloma cells whilst in vivo studies have found increased efficacy of the chemotherapy agent melphalan in the presence of an inhibitor of HIF1α [54, 55].